Skip to content

CorMedix CRMD Payments For Merger Related Costs

Payments For Merger Related Costs at other companies

Installed Building Products logo
Installed Building ProductsIBP
$700K+75.0%
QuinStreet logo
QuinStreetQNST
$2.68M-5.5%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$6.72M
Fluence Energy, Inc. logo
Fluence Energy, Inc.FLNC
$1.47M+4.7%
Zeta Global Holdings logo
Zeta Global HoldingsZETA
$241K-93.4%
Newmark Group, Inc. logo
Newmark Group, Inc.NMRK
$0-100%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForMergerRelatedCosts.

The official record: CorMedix’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's payments for merger related costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's payments for merger related costs?
CorMedix (CRMD) reported payments for merger related costs of $2.55M in Q4 2025.
What does payments for merger related costs mean?
Reflects the cash outflows associated with the acquisition of another business, including legal, advisory, accounting, and integration-related expenses. These costs are distinct from the purchase price of the assets or equity acquired. Tracking these expenses provides insight into the efficiency and total cost burden of inorganic growth strategies.